期刊文献+

Chitosan/pshRNA Plasmid Nanoparticles Targeting MDR1 Gene Reverse Paclitaxel Resistance in Ovarian Cancer Cells 被引量:1

Chitosan/pshRNA Plasmid Nanoparticles Targeting MDR1 Gene Reverse Paclitaxel Resistance in Ovarian Cancer Cells
下载PDF
导出
摘要 In order to investigate the effect of chitosan/pshRNA plasmid nanoparticles targeting MDR1 genes on the resistance of A2780/TS cells to paclitaxel, chitosan/pshRNA plasmid nanoparti- cles were synthesized by means of a complex coacervation technique and transfected into A2780/TS cells. The cells transfected with MDRl-targeted chitosan/pshRNA plasmid nanoparticles were experimental cells and the cells transfected with chitosan/pGPU6/GFP/Neo no-load plasmid nanoparticles served as negative control cells. Morphological features of the nanoparticles were observed under transmission electron microscope (TEM). MDR1 mRNA expression was assessed by RT-PCR. Half-inhibitory concentration (IC50) ofpaclitaxel for A2780/TS cells was determined by MTT method. TEM showed that the nanoparticles were round-shaped, smooth in surface and the diameters varied from 80 to 120 nm. The MDR1 mRNA in the transfected cells was significantly decreased by 17.6%, 27.8% and 52.6% on the post-transfection day 2, 4 and 7 when compared with that in A2780/TS cells control (P〈0.05). MTT assay revealed that the relative reversal efficiency was increased over time and was 29.6%, 51.2% and 61.3% respectively in the transfected cells 2, 4, 7 days after transfection and IC_50 (0.197±0.003, 0.144±0.001, 0.120±0.004) were decreased with difference being significant when compared with that in A2780/TS (0.269±0.003) cells control (P〈0.05). It was concluded that chitosan/pshRNA plasmid nanoparticles targeting MDR1 can effectively reverse the paclitaxel resistance in A2780/TS cells in a time-dependent manner. In order to investigate the effect of chitosan/pshRNA plasmid nanoparticles targeting MDR1 genes on the resistance of A2780/TS cells to paclitaxel, chitosan/pshRNA plasmid nanoparti- cles were synthesized by means of a complex coacervation technique and transfected into A2780/TS cells. The cells transfected with MDRl-targeted chitosan/pshRNA plasmid nanoparticles were experimental cells and the cells transfected with chitosan/pGPU6/GFP/Neo no-load plasmid nanoparticles served as negative control cells. Morphological features of the nanoparticles were observed under transmission electron microscope (TEM). MDR1 mRNA expression was assessed by RT-PCR. Half-inhibitory concentration (IC50) ofpaclitaxel for A2780/TS cells was determined by MTT method. TEM showed that the nanoparticles were round-shaped, smooth in surface and the diameters varied from 80 to 120 nm. The MDR1 mRNA in the transfected cells was significantly decreased by 17.6%, 27.8% and 52.6% on the post-transfection day 2, 4 and 7 when compared with that in A2780/TS cells control (P〈0.05). MTT assay revealed that the relative reversal efficiency was increased over time and was 29.6%, 51.2% and 61.3% respectively in the transfected cells 2, 4, 7 days after transfection and IC_50 (0.197±0.003, 0.144±0.001, 0.120±0.004) were decreased with difference being significant when compared with that in A2780/TS (0.269±0.003) cells control (P〈0.05). It was concluded that chitosan/pshRNA plasmid nanoparticles targeting MDR1 can effectively reverse the paclitaxel resistance in A2780/TS cells in a time-dependent manner.
出处 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 SCIE CAS 2009年第2期239-242,共4页 华中科技大学学报(医学英德文版)
基金 supported by grants from Scientific Research Foundation of Hubei health department (No.JX2B17) a grant from Key Technologies R&D Programme of Hubei Province (No.2007AA301C20)
关键词 MDR1 gene chitosan pshRNA ovarian cancer PACLITAXEL drug resistance MDR1 gene chitosan pshRNA ovarian cancer paclitaxel drug resistance
  • 相关文献

参考文献1

二级参考文献18

  • 1Choi YH, Liu F, Kim JS, et al.Polyethylene glycol-grafted poly-Llysine as polymeric gene carrier [J]. J Control Release, 1998,54( 1 ): 39-48.
  • 2Walter E, Dreher D, Kok M, et al.Hydrophilic poly (DL-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells [J]. J Control Release, 2001,76(1-2): 149-168.
  • 3Richardson SC, Kolbe HV, Duncan R. Potential of low molecular mass chitosan as a DNA delivery system:biocompatibility, body distribution and ability to complex and protect DNA [J]. Int J Pharm, 1999,178(2):231-243.
  • 4Borchard G. Chitosans for gene delivery [J]. Adv Drug Deliv Rev, 2001,52(2): 145-150.
  • 5Janes KA, Calvo P, Alonso MJ.Polysaccharide colloidal particles as delivery systems for macromolecules [J]. Adv Drug Deliv Rev, 2001,47( 1 ): 83-97.
  • 6Kas HS. Chitosan: properties,preparations and application to microparticulate systems [J]. J Microencapsul, 1997,14 (6):689-711.
  • 7Lee JY, Nam SH, Im SY, et al.Enhanced bone formation by controlled growth factor delivery from chitosanbased biomaterials [J]. J Control Release, 2002,78(1-3): 187-197.
  • 8Janes KA, Fresneau MP, Marazuela A, et al. Chitosan nanoparticles as delivery systems for doxorubicin [J]. J Control Release, 2001,73(2-3) :255-267.
  • 9Guang Liu W, De Yao K. Chitosan and its derivatives-a promising nonviral vector for gene transfection [J]. J Control Release, 2002,83(1): 1-11.
  • 10Mao HQ, Roy K, Troung-Le VL, et al. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency [J]. J Control Release, 2001,70 (3) :399-421.

共引文献6

同被引文献1

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部